B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2018
Price : $35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions; Therapeutic Use
- Acronyms BeatMG
- 07 Sep 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 27 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 May 2018.